Net sales were 48,957 million yen, up 24.4% year-over-year. Operating income was 10,164 million yen, ordinary income was 10,708 million yen, and net income attributable to owners of parent for the interim period was 8,000 million yen, a substantial increase. Full-year outlook is net sales of 89,900 million yen and net income of 6,500 million yen. The increase was mainly driven by higher milestone income.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4521","jir_company_name":"Kaken Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4521-20261109-01.pdf","jir_short_summary":"Net sales were 48,957 million yen, up 24.4% year-over-year. Operating income was 10,164 million yen, ordinary income was 10,708 million yen, and net income attributable to owners of parent for the interim period was 8,000 million yen, a substantial increase. Full-year outlook is net sales of 89,900 million yen and net income of 6,500 million yen. The increase was mainly driven by higher milestone income.","jir_summary":"### Overview of Performance\nKaken Pharmaceutical achieved significant increases in the interim period driven mainly by higher milestone income received in the past. Net sales were 48,957 million yen, up 24.4% YoY; operating income was 10,164 million yen; ordinary income was 10,708 million yen; and net income attributable to owners of parent for the interim period was 8,000 million yen. Research and development expenses decreased 14.8% to 9,943 million yen, which together with contributions from milestone income supported improvements in operating and ordinary income.\n\n### Outlook and Key Considerations\nFull-year forecast: net sales 89,900 million yen, operating income 7,900 million yen, ordinary income 8,600 million yen, and net income attributable to owners of parent 6,500 million yen. Revenue and profit growth are expected due to one-time receipts from milestone achievements; however, attention should be paid to the underlying market environment, progress of clinical development, and the sustainability of license income.","jir_financial_highlights":"Net sales: 48,957 (Up 24.4% Year-over-Year (YoY))\nOperating income: 10,164 (Significant increase YoY (prior period 180))\nOrdinary income: 10,708 (Significant increase YoY (prior period 584))\nNet income attributable to owners of parent: 8,000 (Up 698.1% Year-over-Year (YoY))\nResearch and development expenses: 9,943 (Down 14.8% Year-over-Year (YoY))","jir_category":"","jir_hashtags":"#KakenPharmaceutical, #Earnings, #Interim, #LicenseRevenue, #R&DExpenditure","jir_key_figures":"Net sales: 48,957 million yen (Up 24.4% Year-over-Year)\nNet income attributable to owners of parent: 8,000 million yen (Up 698.1% Year-over-Year)\nResearch and development expenses: 9,943 million yen (Down 14.8% Year-over-Year)","jir_meta_title":"Kaken Pharmaceutical Co., Ltd. \u2014 Interim Financial Highlights | Q2 FY2026","jir_meta_description":"Key points from Kaken Pharmaceutical's interim financial summary: year-over-year revenue growth driven by milestone income, increased profitability, full-year outlook and R&D trends summarized.","jir_og_title":"Kaken Pharmaceutical Co., Ltd. Interim Financial Highlights","jir_og_description":"Kaken Pharmaceutical reported significant year-over-year increases in interim revenue and profit. Summary of milestone income impact, R&D trends, and full-year outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9082,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145537","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n